N. White

A Phenotype–Genotype Approach to Predicting CYP450 and P‐Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir

M. Wagner, T. Macgregor, M. Vourvahis, 2010, Clinical pharmacology and therapeutics.

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates

D. Doughty, B. Agoram, Xiaobai Li, 2017, International journal of clinical pharmacology and therapeutics.

Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

P. Vicini, M. Karlsson, B. Agoram, 2018, Clinical pharmacology and therapeutics.

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

M. Braddock, Weichen Xu, Jihong Wang, 2019, Drug Safety.

Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total

P. Vicini, J. Hood, I. González-García, 2021, Pharmaceutics.

Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment

J. Osbourn, A. Celeste, C. Rondinone, 2018, Scientific Reports.

Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment

J. Osbourn, A. Celeste, C. Rondinone, 2018, Scientific Reports.

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus

L. Morrow, G. Carlson, P. Ambery, 2018, Diabetologia.